199 related articles for article (PubMed ID: 15374884)
1. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity.
Zeng Y; Feng H; Graner MW; Katsanis E
Blood; 2003 Jun; 101(11):4485-91. PubMed ID: 12576309
[TBL] [Abstract][Full Text] [Related]
3. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
[TBL] [Abstract][Full Text] [Related]
4. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
Kislin KL; Marron MT; Li G; Graner MW; Katsanis E
FASEB J; 2007 Jul; 21(9):2173-84. PubMed ID: 17327358
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.
Zeng Y; Graner MW; Feng H; Li G; Katsanis E
Int J Cancer; 2004 Jun; 110(2):251-9. PubMed ID: 15069690
[TBL] [Abstract][Full Text] [Related]
6. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity.
Chen X; Zeng Y; Li G; Larmonier N; Graner MW; Katsanis E
Biol Blood Marrow Transplant; 2006 Mar; 12(3):275-83. PubMed ID: 16503496
[TBL] [Abstract][Full Text] [Related]
7. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells.
Feng H; Zeng Y; Graner MW; Katsanis E
Blood; 2002 Dec; 100(12):4108-15. PubMed ID: 12393401
[TBL] [Abstract][Full Text] [Related]
8. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro].
Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ
Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.
Janikashvili N; LaCasse CJ; Larmonier C; Trad M; Herrell A; Bustamante S; Bonnotte B; Har-Noy M; Larmonier N; Katsanis E
Blood; 2011 Feb; 117(5):1555-64. PubMed ID: 21123824
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL-specific CD4
Ueda N; Zhang R; Tatsumi M; Liu TY; Kitayama S; Yasui Y; Sugai S; Iwama T; Senju S; Okada S; Nakatsura T; Kuzushima K; Kiyoi H; Naoe T; Kaneko S; Uemura Y
Cell Mol Immunol; 2018 Jan; 15(1):15-26. PubMed ID: 27181332
[TBL] [Abstract][Full Text] [Related]
12. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Chen W; Qin H; Reese VA; Cheever MA
J Immunother; 1998 Jul; 21(4):257-68. PubMed ID: 9672847
[TBL] [Abstract][Full Text] [Related]
13. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccination against bcr-abl-positive cells in mice.
Lucansky V; Sobotkova E; Tachezy R; Duskova M; Vonka V
Int J Oncol; 2009 Oct; 35(4):941-51. PubMed ID: 19724931
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with leukemia-loaded dendritic cells eradicates residual disease and prevent relapse.
Deeb D; Gao X; Jiang H; Divine G; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2006; 5(3):183-93. PubMed ID: 16528969
[TBL] [Abstract][Full Text] [Related]
16. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
[TBL] [Abstract][Full Text] [Related]
17. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
[TBL] [Abstract][Full Text] [Related]
18. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
Makita M; Azuma T; Hamaguchi H; Niiya H; Kojima K; Fujita S; Tanimoto M; Harada M; Yasukawa M
Leukemia; 2002 Dec; 16(12):2400-7. PubMed ID: 12454745
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
20. Chaperone-rich cell lysates, immune activation and tumor vaccination.
Zeng Y; Graner MW; Katsanis E
Cancer Immunol Immunother; 2006 Mar; 55(3):329-38. PubMed ID: 15887013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]